(Q36411104)

14 August 2017

1 reference

title

Drug Insight: from disturbed motility to disordered movement--a review of the clinical benefits and medicolegal risks of metoclopramide (English)

1 reference

14 August 2017

4

Joseph Jankovic

1 reference

14 August 2017

P Jay Pasricha

1

1 reference

14 August 2017

Nonko Pehlivanov

series ordinal

2

1 reference

14 August 2017

Aravind Sugumar

series ordinal

3

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 March 2006

1 reference

Nature Reviews Gastroenterology & Hepatology

14 August 2017

published in

1 reference

14 August 2017

volume

3

1 reference

14 August 2017

issue

3

1 reference

14 August 2017

page(s)

138-148

1 reference

https://scigraph.springernature.com/pub.10.1038/ncpgasthep0442

14 August 2017

exact match

0 references

cites work

Review article: clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0442

Tardive dyskinesia risks and metoclopramide use before and after U.S. market withdrawal of cisapride

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0442

Metoclopramide in the prevention of postoperative nausea and vomiting: a quantitative systematic review of randomized, placebo-controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0442

RETRACTED: Randomized clinical trial of granisetron, droperidol and metoclopramide for the treatment of nausea and vomiting after laparoscopic cholecystectomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0442

Metoclopramide, thickened feedings, and positioning for gastro-oesophageal reflux in children under two years

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0442

Diabetic gastropathy and prokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0442

American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0442

Prokinetics in patients with gastroparesis: a systematic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0442

Metoclopramide for migration of naso-enteral tube

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0442

Abdominal and pelvic CT: use of oral metoclopramide to enhance bowel opacification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0442

Colonoscopic bowel preparations--which one? A blinded, prospective, randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0442

Efficiency of whole bowel irrigation with and without metoclopramide pretreatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0442

Complete small-bowel transit in patients undergoing capsule endoscopy: determining factors and improvement with metoclopramide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0442

Metoclopramide: an analysis of inappropriate long-term use in the elderly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0442

Efficacy of anticholinergic prophylaxis for neuroleptic-induced acute dystonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0442

Neuroleptic-induced Parkinson's syndrome: clinical features and results of treatment with levodopa

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0442

Neuroleptic induced parkinsonism: MRI findings in relation to clinical course after withdrawal of neuroleptic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0442

Suicide attempts associated with akathisia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0442

Review and videotape recognition of idiopathic restless legs syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0442

Intravenous benztropine and propranolol challenges in tardive akathisia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0442

Riluzole protects from motor deficits and striatal degeneration produced by systemic 3-nitropropionic acid intoxication in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0442

Neuroleptic malignant syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0442

Tardive dyskinesia: prevalence and risk factors, 1959 to 1979.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0442

Heterogeneity of tardive dyskinesia. A multivariate analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0442

Tardive stereotypy and other movement disorders in tardive dyskinesias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0442

A blinded study of the suppressibility of involuntary movements in Huntington's chorea, tardive dyskinesia, and L-dopa-induced chorea

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0442

Extrapyramidal reactions with metoclopramide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0442

The effect of intravenous ranitidine and metoclopramide on behavior, cognitive function, and affect.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0442

Metoclopramide and tardive dyskinesia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0442

Increased incidence of levodopa therapy following metoclopramide use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0442

Long-term effects of tetrabenazine in hyperkinetic movement disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0442

Tetrabenazine treatment in movement disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0442

Pharmacotherapy for intestinal motor and sensory disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0442

Effects of metoclopramide on isolated guinea-pig colon. 2)Interference with ganglionic stimulant drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0442

Effects of metoclopramide on isolated guinea-pig colon. 1)Peripheral sensitization to acetylcholine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0442

Neuroleptic-induced movement disorders: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0442

Regional changes in 2-deoxyglucose uptake associated with neuroleptic-induced tardive dyskinesia in the Cebus monkey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0442

Quantitative light microscopic demonstration of increased pallidal and striatal met5-enkephalin-like immunoreactivity in rats following chronic treatment with haloperidol but not with clozapine: implications for the pathogenesis of neuroleptic-induc

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0442

Evidence of enhanced lipid peroxidation in the cerebrospinal fluid of patients taking phenothiazines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0442

Neuroleptic medications inhibit complex I of the electron transport chain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0442

Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0442

7 January 2021

High-dose versus low-dose metoclopramide in the prevention of cisplatin-induced emesis. A randomized crossover study in patients with ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0442

7 January 2021

When does metoclopramide facilitate transpyloric intubation?

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0442

7 January 2021

A comparison of three methods for performing barium follow-through studies of the small intestine

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0442

7 January 2021

Does metoclopramide reduce the length of ileus after colorectal surgery? A prospective randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0442

7 January 2021

The Effects of Metoclopramide on Postoperative Ileus A Randomized Double-blind Study

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0442

7 January 2021

Abnormal Colonic Motility in Progressive Systemic Sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0442

7 January 2021

Tardive syndromes and other drug-induced movement disorders.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0442

7 January 2021

A survey of drug-induced extrapyramidal reactions

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0442

7 January 2021

Neurologic approach to drug-induced movement disorders: a study of 125 patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0442

7 January 2021

Persistent and progressive parkinsonism after discontinuation of chronic neuroleptic therapy: an additional tardive syndrome?

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0442

7 January 2021

Cinnarizine-induced parkinsonism. Susceptibility related to aging and essential tremor

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0442

7 January 2021

Reversible drug-induced parkinsonism. Clinicopathologic study of two cases

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0442

7 January 2021

High Potency Neuroleptics and Violence in Schizophrenics

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0442

7 January 2021

Neuroleptic malignant syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0442

7 January 2021

Tardive dyskinesia. Patients' lack of awareness of movement disorder

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0442

7 January 2021

The Reversibility of “Permanent” Tardive Dyskinesia

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0442

7 January 2021

Treatment of tardive dyskinesia with bromocriptine. A test of the receptor modification strategy

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0442

7 January 2021

Tardive dyskinesia, dopamine receptors, and neuroleptic damage to cell membranes.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0442

7 January 2021

Excitotoxic Mechanisms May Be Involved in the Pathophysiology of Tardive Dyskinesia

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0442

7 January 2021

Identifiers

DOI

10.1038/NCPGASTHEP0442

1 reference

14 August 2017

1 reference